AN
47
3
SLG
66
4
EXPE
77
5
MTCH
53
3
PSA
56
5
VLO
33
3
CAT
59
4
O
33
-4
WEC
45
4
BLK
69
3
INTC
44
5
HCA
53
3
K
56
5
LUV
40
2
RIG
58
3
GT
60
13
GS
63
11
TDC
47
-39
IPG
50
2
UHS
58
2
AN
47
3
SLG
66
4
EXPE
77
5
MTCH
53
3
PSA
56
5
VLO
33
3
CAT
59
4
O
33
-4
WEC
45
4
BLK
69
3
INTC
44
5
HCA
53
3
K
56
5
LUV
40
2
RIG
58
3
GT
60
13
GS
63
11
TDC
47
-39
IPG
50
2
UHS
58
2
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Buy
73

AKRO
Akero Therapeutics

Last Price:
35.32
Seasonality Move:
25.06%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Akero Therapeutics Price Quote

$35.32
+2.58 (+7.88%)
(Updated: November 6, 2024 at 5:55 PM ET)

Akero Therapeutics Key Stats

Buy
73
Akero Therapeutics (AKRO) is a Buy
Day range:
$31.12 - $32.75
52-week range:
$13.39 - $37.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.85%
Volume:
474K
Avg. volume:
521.3K
1-year change:
124.55%
Market cap:
$2.3B
Revenue:
$0
EPS:
$-3.44

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$190.9M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $368.1M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$311M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

  • Who Are Akero Therapeutics's Competitors?
    Below is a list of companies who compete with Akero Therapeutics or are related in some way:
    • Annovis Bio Inc (ANVS)
    • Amicus Therapeutics Inc (FOLD)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Zoetis Inc (ZTS)

Akero Therapeutics Dividend Yield

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 8.8%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 7
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 46.10
Upside from Last Price: 40.81%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    115.4M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1.3M AKRO shares are owned by insiders